Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AAN | American Academy of Neurology |
| ADA | Antidrug antibody |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| aINCAT | Adjusted Inflammatory Neuropathy Cause and Treatment disability score |
| ALT | Alanine aminotransferase |
| ANA | Antinuclear antibody |
| AST | Aspartate aminotransferase |
| ATC | Anatomical Therapeutic Chemical |
| BLA | Biologics License Application |
| CAGR | Compound annual growth rate |
| CDA-AMC | Canada's Drug Agency (L'Agence des médicaments du Canada) |
| CH50 | Total hemolytic complement activity |
| CHO | Chinese hamster ovary |
| CI | Confidence interval |
| CIDP | Chronic inflammatory demyelinating polyneuropathy |
| CMAP | Compound muscle action potential |
| CMT | Charcot-Marie-Tooth disease |
| CNTN1 | Contactin-1 |
| CSF | Cerebrospinal fluid |
| CTCAE | Common Terminology Criteria for Adverse Events |
| DIL | Drug-induced lupus |
| dsDNA | Double-stranded DNA |
| DSMB | Data and safety monitoring board |
| EAG | External assessment group |
| EAN | European Academy of Neurology |
| EFNS | European Federation of Neurological Societies |
| EQ-5D | EuroQol 5-dimension questionnaire |
| EQ-5D-3L | EuroQol 5-dimension, 3-level questionnaire |
| EQ-5D-5L | EuroQol 5-dimension, 5-level questionnaire |
| EQ-VAS | EuroQol visual analog scale |
| FACIT | Functional Assessment of Chronic Illness Therapy |
| FcRn | Neonatal Fc receptor |
| FDA | U.S. Food and Drug Administration |
| FSS | Fatigue Severity Scale |
| GBS | Guillain-Barré syndrome |
| gMG | Generalized myasthenia gravis |
| HADS | Hospital Anxiety and Depression Scale |
| HCPCS | Healthcare Common Procedure Coding System |
| HRQoL | Health-related quality of life |
| I-RODS | Inflammatory Rasch-built Overall Disability Scale |
| IC90 | Concentration producing 90% inhibition |
| IC95 | Concentration producing 95% inhibition |
| ICD-10 | International Classification of Diseases, Tenth Revision |
| ICER | Incremental cost-effectiveness ratio; Institute for Clinical and Economic Review |
| ICU | Intensive care unit |
| IG | Immunoglobulin |
| IgG | Immunoglobulin G |
| IGIV | Immune globulin intravenous |
| INCAT | Inflammatory Neuropathy Cause and Treatment |
| INN | International nonproprietary name |
| ISR | Injection site reaction |
| IV | Intravenous |
| IVIG | Intravenous immunoglobulin |
| IVIg | Intravenous immunoglobulin |
| IVMP | Intravenous methylprednisolone |
| MAC | Membrane attack complex |
| MAD | Multiple ascending dose |
| MCID | Minimal clinically important difference |
| MMN | Multifocal motor neuropathy |
| MRC | Medical Research Council |
| MRC-SS | Medical Research Council sum score |
| MuSK | Muscle-specific kinase |
| NF155 | Neurofascin-155 |
| NHS | National Health Service |
| NICE | National Institute for Health and Care Excellence |
| NPRS | Numeric Pain Rating Scale |
| OLE | Open-label extension |
| ONLS | Overall Neuropathy Limitations Scale |
| OR | Odds ratio |
| PD | Pharmacodynamics |
| PE | Plasma exchange |
| PK | Pharmacokinetics |
| PLEX | Plasma exchange |
| PNS | Peripheral Nerve Society |
| POEMS | Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome |
| PPV | Positive predictive value |
| Q2W | Every 2 weeks |
| QALY | Quality-adjusted life-year |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| RR | Rate ratio |
| SAD | Single ascending dose |
| SAE | Serious adverse event |
| SC | Subcutaneous |
| SCIG | Subcutaneous immunoglobulin |
| SCIg | Subcutaneous immunoglobulin |
| SD | Standard deviation |
| SEC | U.S. Securities and Exchange Commission |
| SF-36 | 36-Item Short Form Health Survey |
| SLE | Systemic lupus erythematosus |
| SoC | Standard of care |
| TEAE | Treatment-emergent adverse event |
| ULN | Upper limit of normal |
| VAS | Visual analog scale |
| VEGF | Vascular endothelial growth factor |
| WHO | World Health Organization |
| WPAI | Work Productivity and Activity Impairment questionnaire |
| YTE | Tyrosine, threonine, and glutamate substitutions in the Fc domain that extend half-life |